Nemolizumab
Nemolizumab is a monoclonal antibody medication that targets IL-31, a cytokine involved in itch signaling and inflammation. It is primarily used for treating chronic skin conditions characterized by severe pruritus (itching), such as atopic dermatitis and prurigo nodularis. By blocking IL-31 receptor A, it reduces itching, inflammation, and skin damage associated with these conditions.
Nemolizumab is a biologic therapy that treats chronic itchy skin conditions by blocking the IL-31 cytokine, addressing both itch and inflammation.
Key facts at a glance
- ATC
- D11AH12
- RxNorm
- 2691310
- Generic
- Nemolizumab
- Class
- atc-d11
- Brands
- Nemluvio
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Nemolizumab is used to treat chronic pruritic skin disorders, particularly atopic dermatitis and prurigo nodularis, where it helps reduce severe itching and skin inflammation.
As a humanized IgG2 monoclonal antibody, nemolizumab selectively binds to the IL-31 receptor A (IL-31RA), blocking IL-31 signaling. IL-31 is a cytokine that drives pruritus (itching), inflammation, epidermal dysfunction, and fibrosis. By inhibiting this pathway, the medication reduces itch sensation and associated inflammatory responses in the skin.
Nemolizumab is administered via subcutaneous injection. Common side effects may include nasopharyngitis, headache, and upper respiratory infections. As with other biologic therapies, patients should be monitored for potential hypersensitivity reactions and infections. It is typically prescribed by dermatologists for patients with moderate-to-severe symptoms who have not responded adequately to conventional therapies.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy